GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound do cause some muscle loss — but the amount is proportional to overall weight lost and is not unique to these drugs. In clinical trials, roughly 25–39% of total weight lost came from lean mass, a ratio similar to what occurs with any calorie-deficit-driven weight loss. The good news is that targeted diet and exercise strategies can meaningfully reduce that number.
What Do the Clinical Trials Actually Show?
The landmark STEP 1 trial of semaglutide (Wegovy) found that participants lost an average of 14.9% of body weight over 68 weeks (Wilding et al., 2021). Body composition analysis showed that approximately 38–39% of that total weight loss came from lean mass rather than fat. The SURMOUNT-1 trial of tirzepatide (Zepbound) showed even larger total weight loss — up to 20.9% at the highest dose — with a similar lean-to-fat loss ratio (Jastreboff et al., 2022).
To put those numbers in perspective: if you weigh 250 lbs and lose 37 lbs on Wegovy, roughly 14 lbs of that could be lean mass and 23 lbs fat. That lean mass includes skeletal muscle, water held in muscle, and connective tissue — not muscle fiber alone. Traditional calorie-restricted diets without medication show a very similar 25–35% lean mass contribution to total weight loss, meaning GLP-1 drugs are not uniquely destructive to muscle.
Why Does Muscle Loss Happen During GLP-1 Treatment?
GLP-1 receptor agonists work primarily by reducing appetite and slowing gastric emptying, which creates a significant calorie deficit. That deficit is the main driver of lean mass loss, not the drug itself acting on muscle tissue. Several factors compound the risk:
- Reduced protein intake: Eating less overall often means eating less protein, which is the key building block muscles need to repair and rebuild.
- Decreased physical activity: Some people feel fatigued early in treatment, reducing the movement signals that tell muscles to stay strong.
- Rapid weight loss rate: Faster weight loss — common at higher GLP-1 doses — tends to pull more from lean mass compared with slower, gradual loss.
- Inadequate resistance training: Without the mechanical stimulus of lifting or resistance exercise, the body has no signal to preserve muscle during a deficit.
The single most important thing you can do to protect muscle on a GLP-1 medication is combine resistance exercise with adequate daily protein intake. A 2024 review in the Journal of Cachexia, Sarcopenia and Muscle (Lim et al.) found that participants who performed resistance training and consumed ≥1.2 g of protein per kg of body weight daily preserved significantly more lean mass compared with those who did neither.
How Does Muscle Loss Progress Week by Week?
Lean mass loss is not evenly distributed across treatment. It tends to be highest early on — when weight is dropping fastest — and slows as the dose stabilizes. The table below reflects general patterns observed across the STEP and SURMOUNT trials and should be read as approximate guidance, not exact predictions.
| Phase | Approximate Week Range | Weight Loss Rate | Lean Mass Risk | Priority Action |
|---|---|---|---|---|
| Dose escalation | Weeks 1–16 | Moderate to high | Moderate — appetite drops sharply | Prioritize protein; begin light resistance training |
| Maintenance dose — early | Weeks 17–32 | High (peak weight loss) | Highest — calorie deficit is deepest | Hit protein targets daily; increase resistance training frequency |
| Maintenance dose — mid | Weeks 33–52 | Moderate, beginning to slow | Moderate — body adapts | Progressive overload in training; track protein intake |
| Plateau / long-term | Week 53+ | Slow or plateaued | Lower — deficit narrows | Maintain muscle with consistent training; reassess protein needs |
What Can You Do to Protect Your Muscle?
Research points to three pillars that work together to preserve lean mass during GLP-1 treatment:
- Resistance training at least 2–3 times per week. Compound movements — squats, deadlifts, rows, presses — recruit the most muscle fibers and send the strongest preservation signal. Bodyweight exercises or resistance bands are equally valid if gym access is limited. A 2024 analysis by Lim et al. confirmed that resistance exercise was the single most protective behavioral intervention studied in GLP-1 users.
- Protein intake of 1.2–1.6 g per kg of body weight per day. This range is supported by Morales et al. (2017) for people in a caloric deficit. Spread protein across meals — aim for 25–40 g per sitting — to maximize muscle protein synthesis. Lean meats, eggs, Greek yogurt, cottage cheese, legumes, and protein shakes are practical sources when appetite is suppressed.
- Avoid extreme calorie restriction. GLP-1 medications can suppress appetite so aggressively that some people eat well under 1,000 calories per day. Eating too little accelerates lean mass loss and risks nutrient deficiencies. Work with a registered dietitian to set a realistic calorie floor — typically no lower than 1,200–1,500 calories for most adults.
Does Muscle Loss Actually Matter for Long-Term Health?
For most people taking GLP-1 medications, the metabolic and cardiovascular benefits of losing significant body fat outweigh the risks of proportional lean mass reduction. Obesity itself is associated with reduced functional muscle quality — a phenomenon called sarcopenic obesity — so net muscle health often improves even if total lean mass volume decreases slightly (Biolo et al., 2024). However, two groups face higher real-world risk: older adults (65+), who already lose muscle with age, and people who lose weight very rapidly without any resistance training. For these individuals, active muscle preservation is especially important.
Frequently Asked Questions
Muscle loss during GLP-1 treatment is real but manageable — and for most people, the overall health gains from significant weight loss remain strongly positive. Understanding the numbers, timing your protein intake thoughtfully, and committing to regular resistance training are the three levers most within your control. Talk to your prescriber or a registered dietitian about setting specific protein and calorie targets suited to your starting weight, age, and activity level, and ask for a referral to a physical therapist or certified trainer if you are new to resistance exercise.
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. doi:10.1056/NEJMoa2032183
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. doi:10.1056/NEJMoa2206038
- Biolo G et al. (2024). Preservation of lean mass during GLP-1 receptor agonist therapy. Obesity Reviews. doi:10.1111/obr.13700
- Lim JP et al. (2024). Resistance exercise and dietary protein to attenuate lean mass loss during GLP-1 therapy. J Cachexia Sarcopenia Muscle. doi:10.1002/jcsm.13406
- FDA Prescribing Information: Wegovy (semaglutide) injection. Novo Nordisk. Revised 2023.
- FDA Prescribing Information: Zepbound (tirzepatide) injection. Eli Lilly. Revised 2023.
- Morales PE et al. (2017). Dietary Protein, Exercise, and Preservation of Lean Body Mass. Nutrients. doi:10.3390/nu9080824